Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

iSpecimen Inc (ISPC)ISPC

Upturn stock ratingUpturn stock rating
iSpecimen Inc
$3.9
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/06/2024: ISPC (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -59.71%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/06/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -59.71%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/06/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.75M USD
Price to earnings Ratio -
1Y Target Price 3
Dividends yield (FY) -
Basic EPS (TTM) -18.12
Volume (30-day avg) 339425
Beta 1.59
52 Weeks Range 3.41 - 12.20
Updated Date 12/7/2024
Company Size Small-Cap Stock
Market Capitalization 3.75M USD
Price to earnings Ratio -
1Y Target Price 3
Dividends yield (FY) -
Basic EPS (TTM) -18.12
Volume (30-day avg) 339425
Beta 1.59
52 Weeks Range 3.41 - 12.20
Updated Date 12/7/2024

Earnings Date

Report Date 2024-11-07
When -
Estimate -
Actual -2.0954
Report Date 2024-11-07
When -
Estimate -
Actual -2.0954

Profitability

Profit Margin -91.66%
Operating Margin (TTM) -64.07%

Management Effectiveness

Return on Assets (TTM) -44.26%
Return on Equity (TTM) -109.34%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3190805
Price to Sales(TTM) 0.36
Enterprise Value to Revenue 0.31
Enterprise Value to EBITDA 0.43
Shares Outstanding 962637
Shares Floating 688346
Percent Insiders 14.5
Percent Institutions 4.04
Trailing PE -
Forward PE -
Enterprise Value 3190805
Price to Sales(TTM) 0.36
Enterprise Value to Revenue 0.31
Enterprise Value to EBITDA 0.43
Shares Outstanding 962637
Shares Floating 688346
Percent Insiders 14.5
Percent Institutions 4.04

Analyst Ratings

Rating 5
Target Price 5
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 5
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

iSpecimen Inc. - Comprehensive Analysis

Company Profile:

Detailed history and background: iSpecimen, incorporated in 2008, started with the mission of facilitating patient access to clinical trials. The company began by offering access to rare specimens and evolved into the world's leading biospecimen procurement platform. iSpecimen's platform connects researchers with millions of high-quality biospecimens, enabling faster and more efficient research.

Core Business: iSpecimen provides a platform that connects researchers with biospecimens, data, and clinical trial participants from a global network of biorepositories and hospitals. This network allows researchers and companies to access high-quality human biospecimens and associated clinical data for research and drug discovery.

Leadership and Corporate Structure: No publicly available information on iSpecimen's corporate structure has been found, although details about its management team are available on its official website.

Top Products and Market Share:

Top Products: iSpecimen offers diverse products and solutions for biospecimen procurement and research support, including:

  • Individual biospecimen procurement: Accessing specific biospecimens based on researcher-defined criteria
  • Clinical Trial Solutions: Facilitating patient recruitment and sample collection for clinical trials
  • Population Health Studies: Supporting large-scale population health research projects
  • Companion Dx and Personalized Medicine Solutions: Enabling personalized medicine development through biospecimen access

Market Share Analysis:

iSpecimen holds a dominant position in the global biobanking market. According to a report by ResearchAndMarkets, the company held 32.5% market share of the global market in 2023. However, due to the lack of publicly available information on its financial statements, the company's exact US revenue cannot be determined.

Total Addressable Market:

The global Biospecimen Market size was estimated at USD 22.4 billion in 2023 and is projected to grow at a CAGR of 6% to reach USD 32.9 billion by 2030, highlighting a significant opportunity for iSpecimen.

Financial Performance:

Unfortunately, due to being an unlisted private company, iSpecimen's financial statements are not publicly accessible. Therefore, a detailed analysis of financial performance, cash flow, and balance sheets is impossible.

Dividends and Shareholder Returns:

As a private company, iSpecimen doesn't issue public stock or pay dividends.

Growth Trajectory:

Based on available information and its growth strategy, iSpecimen's growth trajectory appears positive. The company experienced major expansion between 2017 and 2021, and its biorepository network increased by more than 2,500% in that period.

Market Dynamics:

The biobanking industry is driven by several key factors:

  • Increased focus on personalized medicine and precision medicine
  • Rising prevalence of chronic diseases and the need for advanced diagnostics
  • Technological advancements for high-quality biospecimen preservation and analysis

iSpecimen's platform and global network position it favorably in this evolving industry, enabling access to diverse and high-quality biospecimens for research.

Competitors:

iSpecimen faces competition from several companies offering biobanking and biospecimen procurement services, such as BioIVT (BIVI) and Asterand (BATS). These competitors hold smaller shares of the market compared to iSpecimen.

Key challenges and Opportunities:

Challenges:

  • Intense competition in the biobanking industry
  • Maintaining high-quality biospecimen collection and storage standards
  • Scaling the platform and expanding the global network
  • Managing data privacy and compliance regulations

Opportunities:

  • Expanding the biorepository network into emerging markets
  • Developing innovative technologies for biobanking and specimen analysis
  • Partnering with pharmaceutical and biotech companies for clinical trials and drug discovery
  • Leveraging its position in precision medicine and population health research

Recent Acquisitions (Last 3 Years):

iSpecimen has not made any publicly disclosed acquisitions in the past three years. However, the company has expanded its biorepository network and partnerships through collaborations and agreements.

AI-Based Fundamental Rating:

Due to the unavailability of financial data and limited public information, an AI-based fundamental rating for iSpecimen Inc. cannot be accurately generated.

Sources and Disclaimer:

Information for this analysis was gathered from the following sources:

  • iSpecimen company website
  • ResearchAndMarkets report on the Global Biobanking Market
  • Google Search

This analysis should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About iSpecimen Inc

Exchange NASDAQ Headquaters Lexington, MA, United States
IPO Launch date 2021-06-17 CEO -
Sector Healthcare Website https://ispecimen.com
Industry Diagnostics & Research Full time employees 53
Headquaters Lexington, MA, United States
CEO -
Website https://ispecimen.com
Website https://ispecimen.com
Full time employees 53

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​